At a glance
- Originator Titan Pharmaceuticals
- Class Antineoplastics; Heavy metals; Organometallic compounds; Pyrones; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Bacterial infections; Bone disorders; Cancer; Malignant hypercalcaemia; Osteitis deformans; Rheumatoid arthritis
Most Recent Events
- 14 Mar 2006 Preclinical trials in Bacterial infections in USA (PO)
- 11 Jul 2005 Data presented at the Annual European Congress of Rheumatology (EULAR-2005) have been added to the Rheumatic disease pharmacodynamics section
- 22 Mar 2005 Preclinical data from a media release have been added to the Rheumatic Disease pharmacodynamics section